Trinity Biotech

Trinity Biotech Treasury Stock

The Treasury Stock of Trinity Biotech (TRIB) as of Nov 10, 2026 is 38.88 M USD. In the previous year, Treasury Stock was 45.18 M USD — a change of -13.96% (lower).

Treasury Stock

38.88 MUSD

YoY

-13.96%

Last updated:

Treasury Stock of Trinity Biotech is 2025 38.88 M USD. Treasury Stock of Trinity Biotech was 2024 45.18 M USD. It decreases by -13.96% lower compared to the previous year.

The Trinity Biotech Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2018
16.19 M USD
Jan 1, 2019
16.19 M USD
Jan 1, 2020
-8.74 M USD
Jan 1, 2021
-8.74 M USD
Jan 1, 2022
28.25 M USD
Jan 1, 2023
21.70 M USD
Jan 1, 2024
45.18 M USD
Jan 1, 2025
38.88 M USD
The Trinity Biotech Treasury Stock history
YEARTreasury StockYoY
38.88 MUSD-13.96%
45.18 MUSD+108.25%
21.70 MUSD-23.18%
28.25 MUSD-423.35%
-8.74 MUSD0.00%
-8.74 MUSD-153.96%
16.19 MUSD0.00%
16.19 MUSD-288.31%
-8.60 MUSD+654.04%
-1.14 MUSD-113.97%
8.16 MUSD+61.40%
5.06 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trinity Biotech Stock analysis

What does Trinity Biotech do? Trinity Biotech Plc develops, manufactures, and markets medical diagnostic products for clinical laboratories and point-of-care segments. The company operates through the Americas and Rest of World segments, offering products classified as POC, emergency medicine, clinical laboratory, and blood bank screening. Its POC brands include Uni-Gold and Recombigen, used for detecting autoimmune, infectious, and sexually transmitted diseases, diabetes, and liver and intestinal disorders. Emergency medicine diagnostics target acute care testing, STAT labs, pre/post-operative units, physician office labs, and central laboratories. The company supplies clinical laboratory market with reagent products and other products through its clinical chemistry business, while its blood bank screening business unit manufactures products to screen donated blood for transfusion-transmissible infections. Trinity Biotech's products serve healthcare providers in clinical and point-of-care settings, with the Americas and Rest of World segments representing key geographic markets for its diagnostic solutions. Trinity Biotech generates revenue from the sale of diagnostic products across multiple segments, including POC testing, emergency medicine diagnostics, clinical chemistry reagents, and blood bank screening. The company's brands, Uni-Gold and Recombigen, are central to its point-of-care offerings, while its clinical chemistry and blood bank screening businesses provide complementary revenue streams in laboratory and blood donation settings. Trinity Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trinity Biotech stock

Treasury Stock of Trinity Biotech is 38.88 M USD in 2025.

Treasury Stock of Trinity Biotech changed from 45.18 M USD to 38.88 M USD, representing a -13.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Trinity Biotech since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Trinity Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Trinity Biotech

All Key Metrics — Trinity Biotech